Cargando…

Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer

BACKGROUND: The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib, combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains unclear. A meta-analysis was performed to address the efficacy and safety of celecoxib in patients with advanced NSCLC. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Lilan, Zhang, Wei, Zhang, Hongman, Shen, Jie, Zou, Jingwen, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086108/ https://www.ncbi.nlm.nih.gov/pubmed/30122902 http://dx.doi.org/10.2147/DDDT.S169627

Ejemplares similares

Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wei, et al.
Publicado: (2020)

Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Hongman, et al.
Publicado: (2018)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Curcumol potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer
por: Cai, Fangfang, et al.
Publicado: (2017)

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Lin, Anqi, et al.
Publicado: (2021)

Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study
por: Jin, Yi-Hua, et al.
Publicado: (2019)

Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes
por: Yang, Qi, et al.
Publicado: (2021)

Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis
por: Cheng, Bai-Ru, et al.
Publicado: (2021)

Metformin Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Non-Small Cell Lung Cancer Cells
por: Cao, Nini, et al.
Publicado: (2020)

Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice
por: Zhang, Bo, et al.
Publicado: (2017)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

Cholestatic Hepatitis with Small Duct Injury Associated with Celecoxib
por: Nayudu, Suresh Kumar, et al.
Publicado: (2013)

Effect of celecoxib on improving depression: A systematic review and meta-analysis
por: Wang, Zhi, et al.
Publicado: (2022)

Deep learning to estimate durable clinical benefit and prognosis from patients with non-small cell lung cancer treated with PD-1/PD-L1 blockade
por: Peng, Jie, et al.
Publicado: (2022)

Celecoxib inhibits insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer
por: LIU, CHEN-HUI, et al.
Publicado: (2013)

Meta-analysis Comparing Celecoxib with Diclofenac Sodium in Patients with Knee Osteoarthritis
por: Huang, Hetao, et al.
Publicado: (2020)

Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
por: Tudor, Diana Valentina, et al.
Publicado: (2021)

Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2011)

Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma
por: Hu, Jun-Wen, et al.
Publicado: (2020)

Structural Modification of Nanomicelles through Phosphatidylcholine: The Enhanced Drug-Loading Capacity and Anticancer Activity of Celecoxib-Casein Nanoparticles for the Intravenous Delivery of Celecoxib
por: Xv, Liuli, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis
por: Luo, Wenqing, et al.
Publicado: (2021)

Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Hu, Xuanbo, et al.
Publicado: (2022)

Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
por: He, Jiayang, et al.
Publicado: (2018)

Identification of key genes and long non-coding RNAs in celecoxib-treated lung squamous cell carcinoma cell line by RNA-sequencing
por: Li, Gang, et al.
Publicado: (2018)

The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus
por: Qian, Jie, et al.
Publicado: (2021)

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
por: Zhou, Jian-Guo, et al.
Publicado: (2015)

Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress
por: Kim, Bomi, et al.
Publicado: (2017)

Celecoxib Blocks Vasculogenic Mimicry via an Off-Target Effect to Radiosensitize Lung Cancer Cells: An Experimental Study
por: Niu, Kai, et al.
Publicado: (2021)

The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ye, Shi-Yu, et al.
Publicado: (2022)

Celecoxib effectively inhibits the formation of joint adhesions
por: LI, FENGFENG, et al.
Publicado: (2013)

The cardiovascular risk of celecoxib for knee osteoarthritis: A protocol for systematic review and meta-analysis
por: Cheng, Shirui, et al.
Publicado: (2020)

Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Gędek, Adam, et al.
Publicado: (2023)

Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity
por: Zhang, Xiangyu, et al.
Publicado: (2020)

Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib
por: Sobolewski, Cyril, et al.
Publicado: (2021)

Pooled analysis of the clinical benefit of cyclooxygenase-2 inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Zheng, Wei, et al.
Publicado: (2019)

Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
por: Fang, Shen-Cun, et al.
Publicado: (2019)

CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter
por: Qiu, Zhengang, et al.
Publicado: (2019)

Challenges and Opportunities for Celecoxib Repurposing
por: Bąk, Urszula, et al.
Publicado: (2023)

Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
por: Zhao, Binghao, et al.
Publicado: (2017)

Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ia5fr749d8sv21v3dgu520mp30